Lancaster Urology
Welcome,         Profile    Billing    Logout  
 3 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sieber, Paul
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Recruiting
3
190
Japan, US, RoW
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
12/27
12/29
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
NCT03914794: A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Hourglass Jan 2021 - Dec 2021 : Updated data from trial for bladder cancer
Recruiting
2
43
US
Pemigatinib, INCB054828, FGFR inhibitor INCB054828
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation
Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma Recurrent
05/25
05/26
ORIC-944-01, NCT05413421: Study of ORIC-944 in Patients with Metastatic Prostate Cancer

Recruiting
1
250
Europe, US, RoW
ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darolutamide (Nubeqa®) 300 mg tablets, Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets
ORIC Pharmaceuticals
Metastatic Prostate Cancer
12/25
09/26
Stern, Dawn
ORIC-944-01, NCT05413421: Study of ORIC-944 in Patients with Metastatic Prostate Cancer

Recruiting
1
250
Europe, US, RoW
ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darolutamide (Nubeqa®) 300 mg tablets, Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets
ORIC Pharmaceuticals
Metastatic Prostate Cancer
12/25
09/26
Slaymacher, Christie
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sieber, Paul
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Recruiting
3
190
Japan, US, RoW
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
12/27
12/29
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
NCT03914794: A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Hourglass Jan 2021 - Dec 2021 : Updated data from trial for bladder cancer
Recruiting
2
43
US
Pemigatinib, INCB054828, FGFR inhibitor INCB054828
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation
Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma Recurrent
05/25
05/26
ORIC-944-01, NCT05413421: Study of ORIC-944 in Patients with Metastatic Prostate Cancer

Recruiting
1
250
Europe, US, RoW
ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darolutamide (Nubeqa®) 300 mg tablets, Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets
ORIC Pharmaceuticals
Metastatic Prostate Cancer
12/25
09/26
Stern, Dawn
ORIC-944-01, NCT05413421: Study of ORIC-944 in Patients with Metastatic Prostate Cancer

Recruiting
1
250
Europe, US, RoW
ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darolutamide (Nubeqa®) 300 mg tablets, Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets
ORIC Pharmaceuticals
Metastatic Prostate Cancer
12/25
09/26
Slaymacher, Christie
No trials found

Download Options